Gene editing Archives

In Depth 25 Sep 2023

Base editing hits the clinic in the U.S.

Over the past couple of years, base editing, a recent offshoot of the heralded CRISPR/Cas 9 technology, has been doing its rounds in the biotech space. Now, base editing has finally set foot into clinical trials for the first time in the U.S.. American precision medicine company Beam Therapeutics treated its first patient with its […]

September 25, 2023 - 7 minutesmins - By Roohi Mariam Peter

Duchenne muscular dystrophy gene therapy

In Depth 7 Sep 2023

Hope for patients with life-threatening muscle disorder after years of clinical trial failures

Duchenne muscular dystrophy is a rare condition that is typically treated with the help of steroids, to manage symptoms, as scientists are yet to close in on a cure. However, the first-ever gene therapy for Duchenne muscular dystrophy is set to open doors for further therapeutic research. As we observe World Duchenne Awareness Day on […]

September 7, 2023 - 8 minutesmins - By Roohi Mariam Peter

In Depth 19 Jul 2023

Genetic engineering giants: is China poised to lead the way?

For many people, when they hear China and genetic engineering in the same sentence, it is often synonymous with scandal, and gene-edited babies may spring to mind. And, although it is true that nearly five years ago, researcher He Jiankui infamously claimed he had created the first ever gene-edited babies, before going to prison for […]

July 19, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 28 Jun 2023

New platform cuts time engineering and selecting genome editors

A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has developed a new way to break through the current limited throughput in optimizing precise genome editors at scale, engineer hundreds of base editor variants in parallel instead of current one-by-one testing, and informing users of the most suitable ones […]

June 28, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 23 May 2023

HuidaGene Therapeutics creates world’s first ‘G to Y’ DNA base-editor

HuidaGene Therapeutics, a clinical-stage genome-editing company, says the National Science Review has published data from its study of the world’s first DNA base editor converting guanine to cytosine/thymine (pyrimidine), or G-to-Y. The company has filed an international patent application for the glycosylase-based guanine base editor (gGBE) and owns the exclusive global rights to the underlying […]

May 23, 2023 - 3 minutesmins - By Jim Cornall

Best in Biotech 4 May 2023

Five advancements in lupus research over the past year

A condition that affects around five million people worldwide, lupus has no proven cure. But various treatments for the disease have been around for more than a century, and lupus research has grown over the years. The first kind of therapy for the autoimmune disease – which occurs due to an overactive immune system that […]

May 4, 2023 - 8 minutesmins - By Roohi Mariam Peter

News and Trends 3 May 2023

Eterna acquires allogeneic immuno-oncology platform from Exacis

Eterna Therapeutics Inc. has announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics. The acquisition complements Eterna Therapeutics’ core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna Therapeutics with an exclusive global license to produce an unlimited number of mRNA-engineered […]

May 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Mar 2023

Beyond Biotech podcast 38: Hello Tomorrow Global Summit

The Hello Tomorrow Global Summit took place in Paris last week (March 8-10), and we feature interviews with four of the participants. Our guests this week are: FreezeM CEO and co-founder, Dr. Yuval Gilad; Allogenica CEO and co-founder Inna Menkova; George Frodsham, founder and CEO of MediSieve; and Poulami Chaudhuri, co-founder, and CEO of Helex […]

March 17, 2023 - 3 minutesmins - By Jim Cornall

In Depth 10 Mar 2023

Can CRISPR bring back extinct animals?

The concept of de-extinction has been around for many years. Once considered a fanciful idea, recent advancements in technology – notably CRISPR – have made bringing back extinct animals such as mammoths an extremely feasible proposition that investors are willing to put their money into, with an aim of reversing and preventing biodiversity loss. The […]

March 10, 2023 - 10 minutesmins - By Willow Shah-Neville

News and Trends 23 Feb 2023

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Moderna, Inc., a biotechnology company working on messenger RNA (mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., an ElevateBio company focused on gene editing technologies and therapeutics, have announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Feb 2023

AI boosts genome editing

Researchers at the University of Zurich have developed a new tool that uses artificial intelligence to predict the efficacy of various genome-editing repair options. Unintentional errors in the correction of DNA mutations of genetic diseases can thus be reduced. Genome editing technologies offer great opportunities for treating genetic diseases. Methods such as the widely used […]

February 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

Milestone for gene-edited therapy for sickle cell disease

Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics have announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application of exa-cel for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The submission is supported by two global phase 3 studies investigating exa-cel as a potential one-time therapy for people with […]

January 26, 2023 - 3 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us